

DAFTAR PUSTAKA

- Almeida, G. C. De, Oliveira, L. F. S., Predes, D., Fokoue, H. H., Kuster, R. M., Oliveira, F. L., Mendes, F. A., & Abreu, J. G. (2020). Piperine suppresses the Wnt / β - catenin pathway and has anti - cancer effects on colorectal cancer cells. *Scientific Reports*, 1–12. <https://doi.org/10.1038/s41598-020-68574-2>
- Assi, H. A., Khoury, K. E., Dbouk, H., Khalil, L. E., Mouhieddine, T. H., & Saghir, N. S. El. (2013). Epidemiology and prognosis of breast cancer in young women. *Journal of Thoracic Disease*, 5(51), 52–58. <https://doi.org/10.3978/j.issn.2072-1439.2013.05.24>
- Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001). Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. *Nature*, 410(6824), 120–124. <https://doi.org/10.1038/35065138>
- Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003). Reversal of human cellular senescence: Roles of the p53 and p16 pathways. *EMBO Journal*, 22(16), 4212–4222. <https://doi.org/10.1093/emboj/cdg417>
- Bolat, Z. B., Islek, Z., Demir, B. N., Yilmaz, E. N., Sahin, F., & Ucisik, M. H. (2020). Curcumin- and Piperine-Loaded Emulsomes as Combinational Treatment Approach Enhance the Anticancer Activity of Curcumin on HCT116 Colorectal Cancer Model. *Frontiers in Bioengineering and Biotechnology*, 8(February), 1–21. <https://doi.org/10.3389/fbioe.2020.00050>
- Bozko, P., Larsen, A. K., Raymond, E., & Skladanowski, A. (2002). Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status. *Acta Biochimica Polonica*, 49(1), 109–119. https://doi.org/10.18388/abp.2002_3827
- Brouckaert, O., Wildiers, H., Floris, G., & Neven, P. (2012). Update on triple-negative breast cancer: Prognosis and management strategies. *International Journal of Women's Health*, 4(1), 511–520.
- Campisi, J. (2013). Aging, cellular senescence, and cancer. *Annual Review of Physiology*, 75, 685–705. <https://doi.org/10.1146/annurev-physiol-030212-183653>
- Campisi, J., & D'Adda Di Fagagna, F. (2007). Cellular senescence: When bad things happen to good cells. *Nature Reviews Molecular Cell Biology*, 8(9), 729–740. <https://doi.org/10.1038/nrm2233>
- Cao, R., & Zhang, Y. (2004). The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. *Current Opinion in Genetics and Development*, 14(2), 155–164. <https://doi.org/10.1016/j.gde.2004.02.001>
- Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007). The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. *Clinical Cancer Research*, 13(8), 2329–2334. <https://doi.org/10.1158/1078-0432.CCR-06-1109>
- Castedo, M., Perfettini, J. L., Roumier, T., Andreau, K., Medema, R., & Kroemer, G. (2004). Cell death by mitotic catastrophe: A molecular definition. *Oncogene*, 23(16 REV. ISS. 2), 2825–2837.

<https://doi.org/10.1038/sj.onc.1207528>

- Chandrashekar, D. S., Bachel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. (2017). UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. *Neoplasia (United States)*, *19*(8), 649–658. <https://doi.org/10.1016/j.neo.2017.05.002>
- Chen, C., Huang, H., & Wu, C. H. (2017). Protein bioinformatics databases and resources. In *Methods in Molecular Biology* (Vol. 1558). https://doi.org/10.1007/978-1-4939-6783-4_1
- Childs, B. G., Durik, M., Baker, D. J., & Van Deursen, J. M. (2015). Cellular senescence in aging and age-related disease: From mechanisms to therapy. *Nature Medicine*, *21*(12), 1424–1435. <https://doi.org/10.1038/nm.4000>
- Chou, T. C., & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. *Advances in Enzyme Regulation*, *22*(C), 27–55. [https://doi.org/10.1016/0065-2571\(84\)90007-4](https://doi.org/10.1016/0065-2571(84)90007-4)
- Choudhuri, S. (2014). The Beginning of Bioinformatics. In *Bioinformatics for Beginners* (pp. 73–76). <https://doi.org/10.1016/b978-0-12-410471-6.00004-9>
- Chow, J. P. H., Poon, R. Y. C., & Ma, H. T. (2011). Inhibitory Phosphorylation of Cyclin-Dependent Kinase 1 as a Compensatory Mechanism for Mitosis Exit. *Molecular and Cellular Biology*, *31*(7), 1478–1491. <https://doi.org/10.1128/mcb.00891-10>
- Collignon, J., Lousberg, L., Schroeder, H., & Jerusalem, G. (2016). Triple-negative breast cancer: Treatment challenges and solutions. *Breast Cancer: Targets and Therapy*, *8*, 93–107. <https://doi.org/10.2147/BCTT.S69488>
- D’Adda Di Fagagna, F. (2008). Living on a break: Cellular senescence as a DNA-damage response. *Nature Reviews Cancer*, *8*(7), 512–522. <https://doi.org/10.1038/nrc2440>
- Da’i, M., Jenie, U. A., Supardjan, A., Meiyanto, E., & Kawaichi, M. (2012). The Effect of PGV-1, PGV-0 and Curcumin on Protein Involve in G2-M Phase of Cell Cycle and Apoptosis on T47D Breast Cancer Cell Line. *Jurnal Ilmu Kefarmasian Indonesia*, *10*(2).
- Daina, A., Michielin, O., & Zoete, V. (2019). SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Research*, *47*(W1), W357–W3664. <https://doi.org/10.1093/nar/gkz382>
- De Angelis, P. M., Svendsrud, D. H., Kravik, K. L., & Stokke, T. (2006). Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. *Molecular Cancer*, *5*, 1–25. <https://doi.org/10.1186/1476-4598-5-20>
- Deng, Y., Sriwiryajan, S., Tedasen, A., & Hiransai, P. (2016). Anti-cancer effects of Piper nigrum via inducing multiple molecular signaling in vivo and in vitro. *Journal of Ethnopharmacology*, *188*, 87–95. <https://doi.org/10.1016/j.jep.2016.04.047>
- Denisenko, T. V., Sorokina, I. V., Gogvadze, V., & Zhivotovsky, B. (2016). Mitotic catastrophe and cancer drug resistance: A link that must to be broken. *Drug*

- Resistance Updates*, 24, 1–12. <https://doi.org/10.1016/j.drup.2015.11.002>
- DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019). Breast cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*, 69(6), 438–451. <https://doi.org/10.3322/caac.21583>
- Do, M. T., Kim, H. G., Choi, J. H., Khanal, T., Park, B. H., Tran, T. P., Jeong, T. C., & Jeong, H. G. (2013). Antitumor efficacy of Piperine in the treatment of human HER2-overexpressing breast cancer cells. *Food Chemistry*, 141(3), 2591–2599. <https://doi.org/10.1016/j.foodchem.2013.04.125>
- Fujita, K. (2019). P53 isoforms in cellular senescence-and ageing-associated biological and physiological functions. *International Journal of Molecular Sciences*, 20(23). <https://doi.org/10.3390/ijms20236023>
- Gil, J., & Peters, G. (2006). Regulation of the INK4b-ARF-INK4a tumour suppressor locus: All for one or one for all. *Nature Reviews Molecular Cell Biology*, 7(9), 667–677. <https://doi.org/10.1038/nrm1987>
- Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H. J. (2009). Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. *Annals of Oncology*, 20(8), 1319–1329. <https://doi.org/10.1093/annonc/mdp322>
- Han, Y., Chin Tan, T. M., & Lim, L. Y. (2008). In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. *Toxicology and Applied Pharmacology*, 230(3), 283–289. <https://doi.org/10.1016/j.taap.2008.02.026>
- Hermawan, A., Fitriyani, A., Junedi, S., Ikawati, M., Haryanti, S., Widaryanti, B., Da'i, M., & Meiyanto, E. (2011). PGV-0 and PGV-1 Increased Apoptosis Induction of Doxorubicin on MCF-7 Breast Cancer cells. *Pharmaceutical Journal of Indonesia*, 11(2), 10–14. <https://doi.org/10.16194/j.cnki.31-1059/g4.2011.07.016>
- Holliday, D. L., & Speirs, V. (2011). Choosing the right cell line for renal cell cancer research. *Breast Cancer Research*, 13, 215–222. <https://doi.org/10.1186/s12943-016-0565-8>
- Horiuchi, D., Kusdra, L., Huskey, N. E., Chandriani, S., Lenburg, M. E., Gonzalez-Angulo, A. M., Creasman, K. J., Bazarov, A. V., Smyth, J. W., Davis, S. E., Yaswen, P., Mills, G. B., Esserman, L. J., & Goga, A. (2012). MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. *Journal of Experimental Medicine*, 209(4), 679–696. <https://doi.org/10.1084/jem.20111512>
- Hwang, Y. P., Yun, H. J., Kim, H. G., Han, E. H., Choi, J. H., Chung, Y. C., & Jeong, H. G. (2011). Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by piperine via the inhibition of PKC α / ERK1 / 2-dependent matrix metalloproteinase-9 expression. *Toxicology Letters*, 203(1), 9–19. <https://doi.org/10.1016/j.toxlet.2011.02.013>
- Itahana, K., Campisi, J., & Dimri, G. P. (2007). Methods to detect biomarkers of cellular senescence: The senescence-associated β -galactosidase assay. *Methods in Molecular Biology*, 371(1), 21–31. <https://doi.org/10.1385/1-59745-361-7:21>

- Jafri, A., Siddiqui, S., Rais, J., Ahmad, M. S., Kumar, S., Jafar, T., Afzal, M., & Arshad, M. (2019). INDUCTION OF APOPTOSIS BY PIPERINE IN HUMAN CERVICAL ADENOCARCINOMA VIA ROS MEDIATED MITOCHONDRIAL PATHWAY AND CASPASE-3 ACTIVATION. *EXCLI Journal*, *18*, 154–164.
- Jiang, M., Zhuang, H., Xia, R., Gan, L., Wu, Y., Ma, J., Sun, Y., & Zhuang, Z. (2017). KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells. *Oncotarget*, *8*(54), 92106–92118. <https://doi.org/10.18632/oncotarget.20785>
- Kakarala, M., Brenner, D. E., Korkaya, H., Cheng, C., Tazi, K., Ginestier, C., Liu, S., Dontu, G., & Wicha, M. S. (2010). Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. *Breast Cancer Research and Treatment*, *122*(3), 777–785. <https://doi.org/10.1007/s10549-009-0612-x>
- Kaur, P., Nagaraja, G. M., Zheng, H., Gizachew, D., Galukande, M., Krishnan, S., & Asea, A. (2012). A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. *BMC Cancer*, *12*(1), 120–132. <https://doi.org/10.1186/1471-2407-12-120>
- Kim, T. H., Shin, S., Yoo, S. D., & Shin, B. S. (2018). Effects of phytochemical P-glycoprotein modulators on the pharmacokinetics and tissue distribution of doxorubicin in mice. *Molecules*, *23*(2). <https://doi.org/10.3390/molecules23020349>
- Korsnes, M. S., & Korsnes, R. (2017). Mitotic catastrophe in BC3H1 cells following yessotoxin exposure. *Frontiers in Cell and Developmental Biology*, *5*(MAR), 1–18. <https://doi.org/10.3389/fcell.2017.00030>
- Kurniawan, S. V., Sugiarti, L., Wanandi, S. I., & Louisa, M. (2018). Piperine in the prevention of the decreased tamoxifen sensitivity in MCF-7 breast cancer cell line. *International Journal of Applied Pharmaceutics*, *10*(Special Issue 1), 335–337. <https://doi.org/10.22159/ijap.2018.v10s1.74>
- Lai, L. H., Fu, Q. H., Liu, Y., Jiang, K., Guo, Q. M., Chen, Q. Y., Yan, B., Wang, Q. Q., & Shen, J. G. (2012). Piperine suppresses tumor growth and metastasis in vitro and in vivo in a 4T1 murine breast cancer model. *Acta Pharmacologica Sinica*, *33*(4), 523–530. <https://doi.org/10.1038/aps.2011.209>
- Larasati, Y. A., Yoneda-kato, N., Nakamae, I., & Yokoyama, T. (2018). Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth. *Scientific Reports*, *January*, 1–13. <https://doi.org/10.1038/s41598-018-20179-6>
- Lestari, B., Nakamae, I., Yoneda-Kato, N., Morimoto, T., Kanaya, S., Yokoyama, T., Shionyu, M., Shirai, T., Meiyanto, E., & Kato, J. ya. (2019). Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence. *Scientific Reports*, *9*(1), 1–12. <https://doi.org/10.1038/s41598-019-51244-3>
- Li, H., Krstin, S., Wang, S., & Wink, M. (2018). Capsaicin and piperine can overcome multidrug resistance in cancer cells to doxorubicin. *Molecules*, *23*(3), 1–11. <https://doi.org/10.3390/molecules23030557>

- Li, S., Lei, Y., Jia, Y., Li, N., Wink, M., & Ma, Y. (2011). *Phytomedicine Piperine , a piperidine alkaloid from Piper nigrum re-sensitizes P-gp , MRP1 and BCRP dependent multidrug resistant cancer cells.* *19*, 83–87. <https://doi.org/10.1016/j.phymed.2011.06.031>
- Liao, Y., Liao, Y., Li, J., Li, J., Fan, Y., & Xu, B. (2018). Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy. *Cancer Management and Research*, *10*, 3801–3808. <https://doi.org/10.2147/CMAR.S174735>
- Liu, M. C., & Gelmann, E. P. (2002). P53 gene mutations: Case study of a clinical marker for solid tumors. *Seminars in Oncology*, *29*(3), 246–257. <https://doi.org/10.1053/sonc.2002.32900>
- Liu, Y., Zhu, Y. H., Mao, C. Q., Dou, S., Shen, S., Tan, Z. Bin, & Wang, J. (2014). Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles. *Journal of Controlled Release*, *192*, 114–121. <https://doi.org/10.1016/j.jconrel.2014.07.001>
- Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006). Modeling the Therapeutic Efficacy of p53 Restoration in Tumors. *Cell*, *127*(7), 1323–1334. <https://doi.org/10.1016/j.cell.2006.12.007>
- Mc Gee, M. M. (2015). Targeting the Mitotic Catastrophe Signaling Pathway in Cancer. *Mediators of Inflammation*, *2015*. <https://doi.org/10.1155/2015/146282>
- Meghwal, M., & Goswami, T. K. (2015). *Nutritional Constituent of Black Pepper as Medicinal Molecules : A Review Chemical Composition , Nutritional , Medicinal And Functional Properties of Black Pepper : A Review.* February, 2–7. <https://doi.org/10.4172/scientificreports.1>
- Meiyanto, E., Husnaa, U., Kastian, R. F., Putri, H., Larasati, Y. A., Khumaira, A., Pamungkas, D. D. P., Jenie, R. I., Kawaichi, M., Lestari, B., Yokoyama, T., & Kato, J. Y. (2021). The target differences of anti-tumorigenesis potential of curcumin and its analogues against HER-2 positive and triple-negative breast cancer cells. *Advanced Pharmaceutical Bulletin*, *11*(1), 188–196. <https://doi.org/10.34172/apb.2021.020>
- Meiyanto, E., Melannisa, R., & Da'i, M. (2006). PGV-1 menurunkan ekspresi faktor angiogenesis (VEGF dan COX-2) pada sel T47D terinduksi estrogen. *Majalah Farmasi Indonesia*, *17*(1), 1–6.
- Meiyanto, E., Putri, D. D. P., Susidarti, R. A., Murwanti, R., Sardjiman, Fitriasari, A., Husnaa, U., Purnomo, H., & Kawaichi, M. (2014). Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. *Asian Pacific Journal of Cancer Prevention*, *15*(1), 179–184. <https://doi.org/10.7314/APJCP.2014.15.1.179>
- Meiyanto, E., Putri, H., Larasati, Y. A., Utomo, R. Y., Jenie, R. I., Ikawati, M., Lestari, B., Yoneda-Kato, N., Nakamae, I., Kawaichi, M., & Kato, J.-Y. (2019). Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation. *Advanced Pharmaceutical*

- Bulletin*, 9(3), 445–452. <https://doi.org/10.15171/jcvtr.2015.24>
- Meiyanto, E., Septisetyani, E. P., Larasati, Y. A., & Kawaichi, M. (2018). Curcumin analog pentagamavunon-1 (PGV-1) sensitizes widr cells to 5-fluorouracil through inhibition of NF- κ B activation. *Asian Pacific Journal of Cancer Prevention*, 19(1), 49–56. <https://doi.org/10.22034/APJCP.2018.19.1.49>
- Mori, Y., Inoue, Y., Taniyama, Y., Tanaka, S., & Terada, Y. (2015). Phosphorylation of the centrosomal protein, Cep169, by Cdk1 promotes its dissociation from centrosomes in mitosis. *Biochemical and Biophysical Research Communications*, 468(4), 642–646. <https://doi.org/10.1016/j.bbrc.2015.11.004>
- Nitta, M., Kobayashi, O., Honda, S., Hirota, T., Kuninaka, S., Marumoto, T., Ushio, Y., & Saya, H. (2004). Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents. *Oncogene*, 23(39), 6548–6558. <https://doi.org/10.1038/sj.onc.1207873>
- Provan, K. G., Leischow, S. J., Keagy, H., & Nodora, J. (2010). Research collaboration in the discovery, development, and delivery networks of a statewide cancer coalition. *Eval Program Plann*, 33(4), 349–355. <https://doi.org/10.1016/j.evalprogplan.2009.12.005>
- Ren, J. X., Gong, Y., Ling, H., Hu, X., & Shao, Z. M. (2019). Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics. *Breast Cancer Research and Treatment*, 173(1), 225–237. <https://doi.org/10.1007/s10549-018-4956-y>
- Reynisdóttir, I., Polyak, K., Iavarone, A., & Massagué, J. (1995). Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF- β . *Genes and Development*, 9(15), 1831–1845. <https://doi.org/10.1101/gad.9.15.1831>
- Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011). Mutations in the p53 tumor suppressor gene: Important milestones at the various steps of tumorigenesis. *Genes and Cancer*, 2(4), 466–474. <https://doi.org/10.1177/1947601911408889>
- Robert S. DiPaola. (2002). To Arrest or Not To G2-M Cell-Cycle Arrest. *Clinical Cancer Research*, 8(November), 3311–3314.
- Roninson, I. B., Broude, E. V., & Chang, B. D. (2001). If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. *Drug Resistance Updates*, 4(5), 303–313. <https://doi.org/10.1054/drup.2001.0213>
- Sari, N. F., Lestari, B., Saputri, D., Ahsani, A. F., Santoso, R. A., Sasmito, E., & Meiyanto, E. (2018). Reveal Cytotoxicity and Antigenotoxicity of Piper nigrum L. Ethanolic Extract and its Combination with Doxorubicin on CHO-K1 Cells. *Indonesian Journal of Cancer Chemoprevention*, 8(3), 110. <https://doi.org/10.14499/indonesianjcanchemoprev8iss3pp110-119>
- Schuler, M., & Green, D. R. (2001). Mechanisms of p53-dependent apoptosis. *Biochemical Society Transactions*, 29(6), 684–688. <https://doi.org/10.1042/bst0290684>
- Selvendiran, K., Thirunavukkarasu, C., Singh, J. P. V., Padmavathi, R., &

- Sakthisekaran, D. (2005). *Chemopreventive effect of piperine on mitochondrial TCA cycle and phase-I and glutathione-metabolizing enzymes in benzo (a) pyrene induced lung carcinogenesis in Swiss albino mice*. 0011, 101–106.
- Shah, M. A., & Schwartz, G. K. (2001). Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. *Clinical Cancer Research*, 7(8), 2168–2181.
- Spoerri, L., Oo, Z. Y., Larsen, J. E., Haass, N. K., Gabrielli, B., & Pavey, S. (2015). *Cell Cycle Checkpoint and DNA Damage Response Defects as Anticancer Targets: From Molecular Mechanisms to Therapeutic Opportunities* (pp. 1–446). QIMR Berghofer Medical Research Institute. <https://doi.org/10.1007/978-94-017-9421-3>
- Sugrue, M. M., Shin, D. Y., Lee, S. W., & Aaronson, S. A. (1997). Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. *Proceedings of the National Academy of Sciences of the United States of America*, 94(18), 9648–9653. <https://doi.org/10.1073/pnas.94.18.9648>
- Sutrisna, E. (2015). Personalized Medicine Digoxin Therapy in Individuals with MDR Gene Polymorphism. *Indonesian Journal of Clinical Pharmacy*, 4(2), 113–119. <https://doi.org/10.15416/ijcp.2015.4.2.113>
- Swift, L. P., Rephaeli, A., Nudelman, A., Phillips, D. R., & Cutts, S. M. (2006). Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. *Cancer Research*, 66(9), 4863–4871. <https://doi.org/10.1158/0008-5472.CAN-05-3410>
- Sztalmachova, M., Gumulec, J., Raudenska, M., Polanska, H., Holubova, M., Balvan, J., Hudcova, K., Knopfova, L., Kizek, R., Adam, V., Babula, P., & Masarik, M. (2015). Molecular response of 4T1-induced mouse mammary tumours and healthy tissues to zinc treatment. *International Journal of Oncology*, 46(4), 1810–1818. <https://doi.org/10.3892/ijo.2015.2883>
- Tao, K., Fang, M., Alroy, J., & Gary, G. G. (2008). Imagable 4T1 model for the study of late stage breast cancer. *BMC Cancer*, 8, 1–19. <https://doi.org/10.1186/1471-2407-8-228>
- Terranova, R., Agherbi, H., Boned, A., Meresse, S., & Djabali, M. (2006). Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. *Proceedings of the National Academy of Sciences of the United States of America*, 103(17), 6629–6634. <https://doi.org/10.1073/pnas.0507425103>
- Thoresen, S. B., Campsteijn, C., Vietri, M., Schink, K. O., Liestøl, K., Andersen, J. S., Raiborg, C., & Stenmark, H. (2014). ANCHR mediates Aurora-B-dependent abscission checkpoint control through retention of VPS4. *Nature Cell Biology*, 16(6), 547–557. <https://doi.org/10.1038/ncb2959>
- Tishler, R. B., & Lamppu, D. M. (1996). The interaction of taxol and vinblastine with radiation induction of p53 and p21(WAF1/CIP1). *British Journal of Cancer*, 74(SUPPL. XXVII).
- Tseng, L. M., Hsu, N. C., Chen, S. C., Lu, Y. S., Lu, C. H., Chang, D. Y., Li, H., Lin, Y. C., Chang, H. K., Chao, T. C., & Hou, M. F. (2013). Distant metastasis in triple-negative breast cancer. *Neoplasma*, 60(3), 607–616.